As methylphenidate (MPH) can increase the availability of extracellular DA in the synaptic gap by blocking dopamine transporter protein (DAT) (Faraone, 2018; Rostami Kandroodi et al., 2021), it has been used as a first-line drug for the treatment of ADHD. Here, SLC6A3 is linked to attention deficit-hyperactivity disorder.